Balance Sheet
Cash Flow Statement
AmortizationAmortization of Deferred ChargesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Free Cash Flow (2023 - 2025)

Historic Free Cash Flow for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to -$2.1 million.

  • BioLineRx's Free Cash Flow rose 7856.49% to -$2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.5 million, marking a year-over-year increase of 5532.67%. This contributed to the annual value of -$43.8 million for FY2024, which is 9482.48% down from last year.
  • According to the latest figures from Q3 2025, BioLineRx's Free Cash Flow is -$2.1 million, which was up 7856.49% from -$177000.0 recorded in Q2 2025.
  • BioLineRx's 5-year Free Cash Flow high stood at $5.0 million for Q4 2023, and its period low was -$14.1 million during Q1 2024.
  • For the 3-year period, BioLineRx's Free Cash Flow averaged around -$6.5 million, with its median value being -$8.6 million (2024).
  • In the last 5 years, BioLineRx's Free Cash Flow crashed by 27207.91% in 2024 and then surged by 9843.39% in 2025.
  • Over the past 3 years, BioLineRx's Free Cash Flow (Quarter) stood at $5.0 million in 2023, then plummeted by 272.08% to -$8.6 million in 2024, then soared by 75.56% to -$2.1 million in 2025.
  • Its Free Cash Flow stands at -$2.1 million for Q3 2025, versus -$177000.0 for Q2 2025 and -$2.6 million for Q1 2025.